左旋多巴片联合丁苯酞治疗帕金森病认知障碍临床效果

Clinical observation of levodopa tablets combined with butylphthalide in the treatment of cognitive impairment in Parkinson's disease

目的:观察左旋多巴片联合丁苯酞治疗帕金森病认知障碍临床效果。方法:选取2018年2月至2020年5月收治的114例帕金森病伴认知障碍患者为研究对象,随机分为观察组和对照组;对照组患者进行左旋多巴片治疗,观察组患者进行左旋多巴片联合丁苯酞治疗;比较两组患者的临床疗效,治疗前后MoCA、MMSE、PDQ-39、MESS评分及HCY水平。结果:观察组患者的临床疗效总有效率为94.74%,高于对照组患者的82.46%(P<0.05);治疗前两组患者的MoCA、MMSE、PDQ-39、MESS评分比较,差异无统计学意义(P>0.05);治疗后观察组患者的MoCA、MMSE、PDQ-39、MESS评分均高于对照组(P<0.05);治疗前两组患者的HCY水平比较,差异无统计学意义(P>0.05);治疗后观察组患者的HCY水平下降幅度高于对照组(P<0.05)。结论:左旋多巴片联合丁苯酞治疗帕金森病伴认知障碍可提高临床疗效,促进神经功能恢复,提高生活质量,HCY水平降低,促进认知功能改善。

Objective:To explore and analyze the clinical effects of levodopa tablets combined with butylphthalide in the treatment of cognitive impairment in Parkinson's disease;Method:Select 114 patients with Parkinson's disease and cognitive impairment who were admitted from February 2018 to May 2020 and divided into observation Group and control group.The control group was treated with levodopa tablets,and the observation group was combined with butylphthalide.The clinical effects of the two groups were compared,and the MoCA,MMSE,PDQ-39,MESS scores and HCY levels before and after treatment were compared;Results:the clinical efficacy of the observation group The total effective rate of 94.74%was significantly higher than that of the control group's 82.46%(P<0.05).There was no significant difference in MoCA,MMSE,PDQ-39,and MESS scores between the two groups before treatment(P>0.05).After treatment,MoCA and MESS in the observation group,SF-36 score increased,PDQ score decreased more significantly(P<0.05),there was no significant difference in HCY levels between the two groups before treatment(P>0.05),and HCY levels in the observation group decreased more significantly after treatment(P<0.05);Conclusion:Levodopa tablets combined with butylphthalide in the treatment of Parkinson’s disease with cognitive impairment significantly improve the clinical efficacy,promote the recovery of patients’neurological function,improve their cognitive impairment symptoms,improve the quality of life,and significantly reduce the patient’s HCY level to promote cognition Improvement of obstacles.